51 completed, 21 unknown, 17 recruiting, 10 not yet recruiting. 32 Phase 2, 23 Phase 3, 19 Phase 4, 17 Not applicable, 11 Phase 1.
Follow IgA Nephropathy: new trials by email Literature Review of IgA Nephropathy trials Research Report on IgA Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 10 | 2028-02-01 | 2026-04-13 |
| Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab, Standard of care - IgA Nephropathy | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | 2026-10-30 | 2026-10-15 |
| A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants Budesonide delayed release tablet - IgA Nephropathy | Phase 1 | Not yet recruiting | Triastek, lnc. | 18 | 2026-10-01 | 2026-10-27 |
| MYTP01 for Immune-Mediated Diseases MYTP01, MYTP01 Placebo - IgA Nephropathy, Kidney Transplant Recipients | Not applicable | Not yet recruiting | Zhejiang Provincial People's Hospital | 160 | 2026-10-01 | 2026-10-28 |
| Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy Mycophenolate Mofetil (MMF), Prednisolon - IgA Nephropathy | Phase 2 | Not yet recruiting | Shaheed Suhrawardy Medical College and Hospital | 104 | 2026-09-01 | 2026-08-25 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Drug: Atrasentan - Berger Disease, Bergers Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 28 | 2026-08-06 | 2026-10-15 |
| A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G ADX-097 - IgA Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Akebia Therapeutics | 30 | 2026-07-30 | 2026-10-01 |
| A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy BHV-1400, Placebo - IgA Nephropathy | Phase 3 | Not yet recruiting | Biohaven Therapeutics Ltd. | 420 | 2026-06-01 | 2026-06-11 |
| IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection IgA Nephropathy | Not yet recruiting | Novartis Pharmaceuticals | 80 | 2026-05-29 | 2026-03-18 | |
| A Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101 - IgA Nephropathy | Phase 2 | Recruiting | Jade Biosciences, Inc. | 30 | 2026-05-19 | 2026-09-25 |
| A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United States IGA Nephropathy | Completed | Novartis Pharmaceuticals | 6286 | 2026-03-12 | 2026-08-11 | |
| Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis ANCA Associated Vasculitis, Extramembranous Glomerulopathy | Recruiting | Assistance Publique - Hôpitaux de Paris | 146 | 2025-11-03 | 2026-06-30 | |
| Nefecon and Ambrisentan in IgA Nephropathy "Nefecon®","Ambrisentan" - IgA Nephropathy, Chronic Kidney Disease | Phase 4 | Recruiting | The First Hospital of Jilin University | 129 | 2025-09-01 | 2025-09-15 |
| Study of CM313 in Subject With IgA Nephropathy CM313, Placebo - IgA Nephropathy | Phase 2 | Not yet recruiting | Keymed Biosciences Co.Ltd | 106 | 2025-09-01 | 2025-09-19 |
| Study of BHV-1400 in IgA Nephropathy BHV-1400 - IgA Nephropathy | Phase 1 | Recruiting | Biohaven Therapeutics Ltd. | 20 | 2025-07-30 | 2026-06-23 |
| A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. RD06-05 CART Cell Injection - SLE, LN | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 96 | 2025-07-24 | 2026-08-03 |
| A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects HRS-5965 Capsules - IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 16 | 2025-06-30 | 2025-08-20 |
| Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study Hydroxychloroquine Oral Tablet, Placebo oral tablet - IgA Nephropathy | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 334 | 2025-06-26 | 2026-10-09 |
| Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC - IgA Nephropathy, Renal Insufficiency, Chronic | Phase 4 | Recruiting | Christian Medical College, Vellore, India | 585 | 2025-02-15 | 2025-07-14 |
| Serum and Urinary sCD163 in IgA Nephropathy IgA Nephropathy | Completed | Bezmialem Vakif University | 87 | 2025-02-03 | 2026-10-27 |
Showing 20 of 120. Sign in to see all of them.
Glomerulonephritis, IGA (120) · Proteinuria (28) · Glomerulonephritis (14) · Renal Insufficiency, Chronic (13) · Kidney Diseases (11) · Glomerulosclerosis, Focal Segmental (7) · Urologic Diseases (7) · Glomerulonephritis, Membranous (6) · Lupus Nephritis (5) · Diabetic Nephropathies (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Kidney Failure, Chronic (3) · Nephritis (3) · Nephrosis, Lipoid (3) · Glomerulonephritis, Membranoproliferative (2)
Female Urogenital Diseases (120) · Female Urogenital Diseases and Pregnancy Complications (120) · Male Urogenital Diseases (120) · Autoimmune Diseases (119) · Immune System Diseases (119) · Urogenital Diseases (119) · Nephritis (117) · Urologic Diseases (113) · Kidney Diseases (109) · Glomerulonephritis (106) · Pathological Conditions, Signs and Symptoms (38) · Signs and Symptoms (29) · Urination Disorders (29) · Urological Manifestations (28) · Pathologic Processes (18)
Mycophenolic Acid (10) · Prednisone (8) · Angiotensin-Converting Enzyme Inhibitors (5) · Atrasentan (5) · Prednisolone (5) · Adrenal Cortex Hormones (3) · Cyclophosphamide (3) · Methylprednisolone (3) · aliskiren (3) · AMG623 peptibody (2) · Adenosine Triphosphate (2) · Angiotensin Receptor Antagonists (2) · Azathioprine (2) · Bortezomib (2) · Budesonide (2)
Novartis Pharmaceuticals (11) · Guangdong Provincial People's Hospital (6) · Sun Yat-sen University (6) · Chinese University of Hong Kong (3) · Nanjing University School of Medicine (3) · Otsuka Pharmaceutical Development & Commercialization, Inc. (3) · A. Manzoni Hospital (2) · Anthera Pharmaceuticals (2) · Arrowhead Pharmaceuticals (2) · Assistance Publique - Hôpitaux de Paris (2) · Biohaven Therapeutics Ltd. (2) · Calliditas Therapeutics AB (2) · Centre Hospitalier Universitaire de Saint Etienne (2) · Keymed Biosciences Co.Ltd (2) · Peking University First Hospital (2)
China (52) · United States (27) · South Korea (17) · United Kingdom (16) · Australia (11) · France (10) · Germany (10) · Spain (9) · Taiwan (9) · Hong Kong (8) · Argentina (7) · Canada (7) · India (7) · Japan (7) · Malaysia (7)
Jicheng Lv (3) · Jingyuan Xie (2) · Xueqing Yu, MD (2) · Ahmed Boumediene, doctor (1) · Anping Xu, MD (1) · Antonello Pani, MD (1) · Bryan Curtis, M.D. (1) · Byung-Joo Park, MD,PhD,FISPE (1) · Cheuk Chun Szeto, MD (1) · Cheuk-Chun Szeto, MD (1) · Choli Hartono, MD (1)
PMID 38299639, PMID 38864363, PMID 26032537, PMID 26630142, PMID 37772889, PMID 35675911, PMID 40482854, PMID 41442197, PMID 10093981, PMID 10676716, PMID 11877568, PMID 14694168, PMID 16014059, PMID 18436082, PMID 18587715, PMID 21680850, PMID 22995802, PMID 23675422, PMID 23782179, PMID 23787555, PMID 23977072, PMID 24191893, PMID 24641955, PMID 27821627, PMID 28341274, PMID 28395659, PMID 28763548, PMID 29988921, PMID 30177021, PMID 32842999, PMID 34124781, PMID 35570983, PMID 36745456, PMID 37036696, PMID 37254256, PMID 37914086, PMID 38059359, PMID 38724717, PMID 39453772, PMID 39460694, PMID 39462308, PMID 39462310, PMID 39899371, PMID 40297949, PMID 40357496, PMID 40465397, PMID 40627446, PMID 40938675, PMID 41196369, PMID 41620980
2016 (2), 2023 (2), 2005 (1), 2014 (1), 2017 (1), 2018 (1)